{ 143件 }
Favorable effect of pemafibrate on insulin resistance and β-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study Hiroshi Nomoto, Kenichi Kito, Hiroshi Iesaka, Yuki Oe, Shinichiro Kawata, Kazuhisa Tsuchida, Shingo Yanagiya, Aika Miya, Hiraku Kameda, Kyu Yong Cho, Ichiro Sakuma, Naoki Manda, Akinobu Nakamura, Tatsuya Atsumi Pharmaceutics, in press IF 6.525
アメリカ内分泌学会（ENDO 2023）Outstanding Abstract Award 桑原 咲先生
Aika Miya, Akinobu Nakamura, Yuka Suzuki, Hiroshi Nomoto, Hiraku Kameda, Kyu Yong Cho, Yoichi M. Ito, So Nagai, Hideaki Miyoshi, Tatsuya Atsumi Inverse association between glucose variability and body fat in type 2 diabetes with impaired endogenous insulin secretion using continuous glucose monitoring: a prospective observational study Diabetes, Obesity and Metabolism, in press
IF: 6.408
Nomoto H.
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes World J Diabetes
IF：4.560
Takako Araki, Hiraku Kameda, Masaaki Yamamoto, Toru Tateno, Yasumasa Iwasaki, Run Yu, Constance Chik, Hiba Hashmi, Angela Radulescu, Lynn A Burmeister, Hidenori Fukuoka The impact of multi-cultural interfacility video case conference – A novel education model after the COVID pandemic – Journal of the Endocrine Society, in press.
IF：なし
Takahashi Y, Nomoto H*, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H*.
Improvement of glycemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicenter, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1
study)
Diabetes Obes Metab, in press
IF = 6.408
Miyoshi H, Matsuhisa M, Yabe D, Takahashi Y, Morimoto Y, Terauchi Y.
Use of iGlarLixi for the management of type 2 diabetes in Japanese clinical practice: prior treatment subgroup analysis of the SPARTA Japan study.
Diabetes Ther. 2023 in press
IF = 3.605
Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T, Miyoshi H.
Effect of beta-cell function on glucose variability when switching from insulin degludec plus a dipeptidyl peptidase-4 inhibitor to insulin degludec/liraglutide: preliminary results from a pilot study Int J Endocrinol, in press.
IF：2.803
Nomoto H, Takahashi A, Nakamura A, Kurihara H, Takeuchi J, Nagai S, Taneda S, Kameda H, Miya A, Cho KY, Miyoshi H, Atsumi T.
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl
peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study) BMJ Open Diab. Res. Care., in press
IF: 4.179、5-year IF：4.270